Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-inflammatory, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, antifungals, corticosteroids, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, soft gelatin capsules, dry syrup, gripe water, and oral gel, powder, and liquid in the cardiovascular and anti-diabetics areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, and ROIVIT; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, creams, lotions, liquids, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.
Metrics to compare | KIDI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKIDIPeersSector | |
---|---|---|---|---|
P/E Ratio | 42.7x | 30.4x | −0.6x | |
PEG Ratio | 10.12 | 0.06 | 0.00 | |
Price/Book | 3.0x | 3.4x | 2.6x | |
Price / LTM Sales | 3.6x | 2.8x | 3.2x | |
Upside (Analyst Target) | - | −3.6% | 44.2% | |
Fair Value Upside | Unlock | −8.7% | 7.9% | Unlock |